

1 **Mitogen and Stress-Activated Kinases 1 and 2 Mediate Endothelial Dysfunction**

2 **Short title: MSK1/2, Inflammation and Endothelial Function**

3 Naveed Akbar<sup>1</sup> PhD, Calum Forteach<sup>1</sup> PhD, Muhammad S. Hussain<sup>1</sup> MSc, Kathleen Reyskens<sup>2</sup>

4 PhD, Jill J. F. Belch<sup>1</sup> MD, FRCP, Chim C. Lang<sup>1</sup> MD, FRCP, Ify Mordi<sup>1</sup> MD, FRCP, U Bhalraam,

5 BMSc, MBChB, J. Simon C. Arthur<sup>2</sup> DPhil, Faisal Khan<sup>1</sup> PhD

6 <sup>1</sup>The Institute of Cardiovascular Research, Ninewells Hospital and Medical School, University of

7 Dundee, Dundee, UK.

8 <sup>2</sup>Cell Signalling and Immunology Unit, College of Life Sciences, University of Dundee, Dundee,

9 UK.

10 **Corresponding Authors**

11 Dr Naveed Akbar and Professor Faisal Khan

12 The Institute of Cardiovascular Research

13 Ninewells Hospital and Medical School,

14 University of Dundee, Dundee,

15 DD19SY

16 UK

17 Tel: +44(1382) 383531

18 Fax: +44 (1382) 632333

19 E-mail:

20 [Naveed.akbar@cardiov.ox.ac.uk](mailto:Naveed.akbar@cardiov.ox.ac.uk)

21 [F.Khan@dundee.ac.uk](mailto:F.Khan@dundee.ac.uk)

22 **Word Count:** 8349

23 **Key words:** Endothelium, Vascular Biology, Vascular Disease, MAPK, Cytokine

24 **Conflict of interest statement**

25 The authors have declared that no conflict of interest exists.

26

27

28 **ABSTRACT**

29 Inflammation promotes endothelial dysfunction. Using translational vascular function testing in  
30 myocardial Infarction patients, a situation where inflammation is prevalent, and knock-out (KO)  
31 mouse models we demonstrate a role for mitogen-activated-protein-kinases (MAPKs) in  
32 endothelial dysfunction. Myocardial infarction significantly lowers mitogen and stress kinase 1/2  
33 (MSK1/2) expression in peripheral blood mononuclear cells and diminished endothelial function.  
34 To further understand the role of MSK1/2 in vascular function we developed *in vivo* animal models  
35 to assess vascular responses to vasoactive drugs using laser Doppler imaging. Genetic deficiency  
36 of MSK1/2 in mice increased plasma levels of pro-inflammatory cytokines and promoted  
37 endothelial dysfunction, through attenuated production of nitric oxide (NO), which were further  
38 exacerbated by cholesterol feeding. MSK1/2 are activated by toll-like receptors through MyD88.  
39 MyD88 KO showed preserved endothelial function and reduced plasma cytokine expression,  
40 despite significant hypercholesterolemia. MSK1/2 kinases interact with MAPK-activated proteins  
41 2/3 (MAPKAP2/3), which limit cytokine synthesis. Cholesterol-fed MAPKAP2/3 KO mice showed  
42 reduced plasma cytokine expression and preservation of endothelial function. MSK1/2 plays a  
43 significant role in the development of endothelial dysfunction and may provide a novel target for  
44 intervention to reduce vascular inflammation. Selective activation of MSK1/2 could reduce pro-  
45 inflammatory responses and preserve endothelial function before development of significant  
46 vascular disease.

47

## 18 **Abbreviations**

19	AMI	Acute myocardial infarction
50	AU	Arbitrary unit
51	AUC	Area under Curve
52	BMI	Body mass index
53	CVD	Cardiovascular disease
54	DMSO	Dimethyl sulfoxide
55	EDTA	Ethylenediaminetetraacetic acid
56	EGTA	Ethylene glycol tetraacetic acid
57	FBS	Foetal bovine serum
58	FMD	Flow mediated dilation
59	GTN	Glyceryl trinitrate
50	HDL	High-density lipoprotein
51	HV	Healthy volunteers
52	IL-	interleukin-
53	KO	Knock-out
54	LDL	Low density lipoprotein
55	LPS	Lipopolysaccharide
56	LV	Left ventricle
57	MAPK	Mitogen activate protein kinase
58	MAPKAPK	Mitogen activate protein kinase-activated kinase
59	MSK	Mitogen and stress kinase
70	MSRU	Medical school resource unit
71	NO	Nitric oxide
72	NOS	Nitric oxide synthase
73	PBMC	Peripheral blood mononuclear cell

74	PBS	Phosphate buffered saline
75	PCI	Percutaneous coronary intervention
76	PCR	Polymerase chain reaction
77	PE	Phenylephrine
78	ROI	Region of interest
79	RPM	Rounds per minute
30	SD	Standard deviation
31	SNP	Sodium nitroprusside
32	STEMI	ST-Elevation Myocardial Infarction
33	TLR	Toll-like receptor
34	TNF	Tumour necrosis factor
35	WT	Wild-type

## 36 INTRODUCTION

37 Inflammation is a major driver in the development of atherosclerosis (1-3). It promotes early  
38 endothelial dysfunction (4) as well as playing an important role in ischemia reperfusion following  
39 acute myocardial infarction (AMI). Blood cytokines are predictive of future adverse cardiovascular  
40 events (5-7), and local inflammation in tissues is associated with tissue injury and immune cell  
41 recruitment. Cytokine release can be induced through numerous pathways. Importantly, toll-like  
42 receptors (TLRs) induce the expression of pro-inflammatory genes that are associated with  
43 atherosclerosis (8). TLRs are also upregulated on peripheral blood monocytes following AMI (9)  
44 and on activated endothelial cells (10, 11). The regulation of cytokine expression downstream of  
45 TLRs is complex and involves recruitment of myeloid differentiation primary response-88 (MyD88),  
46 initiating downstream signals through multiple signalling pathways, including p38 $\alpha$  mitogen-  
47 activated protein kinase (MAPK). Inhibition of p38 in a model of atherosclerosis reduces plaque  
48 formation (12) and preserves cardiac function in a model of heart failure (13). However, clinical  
49 trials of p38 inhibition have shown no therapeutic effect on cardiovascular disease (CVD) outcome  
50 (14).

51  
52 While p38 $\alpha$  has inflammatory roles, recent work shows it can also have anti-inflammatory  
53 functions (15). For example, mice with a myeloid specific deletion in p38 $\alpha$  show increased  
54 pathology in an ultraviolet-B induced skin inflammation model (16). The effects of p38 in  
55 inflammation are in part mediated by two groups of downstream kinases, mitogen and stress  
56 kinase (MSK)1 and 2 and MAPK-activated protein kinases (MAPKAPK) 2 and 3. MSK1 and 2  
57 have been found to be important in mediating the anti-inflammatory functions of p38 $\alpha$  (16, 17).  
58 MSK1 and 2 are nuclear kinases that are activated downstream of p38 $\alpha$  MAPK and serve to help  
59 regulate the induction of immediate early genes (18). TLR signalling in macrophages has been  
60 shown to activate MSKs and this promotes transcription of several genes with anti-inflammatory  
61 functions including interleukin-10 (IL-10) and IL-1 receptor antagonist (IL-1ra) (16, 17, 19). MSKs

12 also regulate the induction of a dual specificity phosphatase (DUSP1) (16), which is involved in  
13 deactivation of p38 $\alpha$  and c-Jun N-Terminal kinases (JNK) downstream of TLR signalling (20).  
14 Consequently, MSK1/2 double knockout (KO) mice show increased sensitivity to liposaccharide  
15 (LPS) induced endotoxic shock, which is accompanied by increased induction of tumour necrosis  
16 factor (TNF), interleukin-6 (IL-6) and IL-12 relative to wild-type (WT) animals (16). In contrast to  
17 MSKs, MAPKAPK2/3 are important in mediating the pro-inflammatory effects of p38 $\alpha$ .  
18 MAPKAPK2 deficient animals display significant attenuation of TNF- $\alpha$  production in response to  
19 LPS (21), resistance to the development of rheumatoid arthritis (RA) (22), and a reduction in  
20 atherosclerotic lesion formation (23). However, the role of TLR kinases in the development of early  
21 vascular inflammation and endothelial dysfunction remains unknown.

22

23 The aim of the present study was to examine the role of MSKs in CVD. AMI is associated with  
24 substantial impairment of endothelial function and inflammation in both the infarcted myocardium  
25 and myocardium perfused by normal vessels (24, 25). The determinants of endothelial dysfunction  
26 that contribute to the extent of ischemia and necrosis after AMI are not fully elucidated. It is not  
27 known if MSK1/2 are involved in endothelial dysfunction following AMI. In this study, we examined  
28 patients presenting with AMI, and obtained peripheral blood mononuclear cells (PBMCs) for  
29 evaluation of MSK1/2 expression and to determine the association of this expression with  
30 endothelial function *in vivo*. We hypothesised that there is a link between expression of MSK1/2  
31 and endothelial dysfunction. To examine this relationship in more detail, we used an *in vivo*  
32 MSK1/2 KO mouse model to longitudinally assess the functional role of MSK1/2 in development of  
33 endothelial dysfunction, a known precursor for CVD development. Additionally, we used MyD88  
34 and MAPKAPK2/3 deficient mouse models to examine proteins upstream and downstream of  
35 p38 $\alpha$  to better understand the role of innate immune signalling in the development of endothelial  
36 dysfunction *in vivo*.



38 **RESULTS**

39 **MSK1/2 gene expression in ST-elevation myocardial Infarction (STEMI) patients**

40 To investigate the roles of MSK in human cardiovascular disease, we recruited patients who had  
41 recently suffered STEMI and undergone PCI. Thirty-five patients who were admitted to Ninewells  
42 Hospital Coronary Care Unit provided written, informed consent for collection of bloods for the  
43 isolation of PBMCs and for vascular function testing using FMD of the brachial artery. A further  
44 twenty-eight age-matched healthy volunteers (HV) were recruited to undergo the same tests as  
45 the STEMI patients (**Table 1**). MSK1 and MSK2 gene expression was significantly lower in  
46 PBMCs from STEMI patients when compared with HV controls (STEMI MSK1 ( $P<0.001$ ) and  
47 MSK2 ( $P<0.001$ ) were 1.2-fold lower vs HV) (**Figure 1 A/B**, respectively).

48  
49 We have previously reported elevated expression of inflammatory cytokines and microvascular  
50 dysfunction in patients suffering from rheumatoid arthritis (26) and in an animal model of systemic  
51 lupus erythematosus (27), supporting a role for systemic inflammation and innate immune  
52 signalling in endothelial-dependent vascular impairment.

53  
54 We assessed endothelial function by measuring FMD in our STEMI patients and found they had  
55 significantly lower vascular responses compared with HV controls ( $3.7\pm 1.3$  % vs.  $6.8\pm 1.9$  %,  $P<0.001$ ) (**Figure 1C**). Additionally, the endothelium-independent response to GTN was  
56 significantly lower in STEMI patients compared with healthy HV ( $8.2\pm 0.7$  % vs.  $17.8\pm 1.3$  %,  $P<0.001$ ). The percentage change in velocity time integral (AUC), as an indicator of microvascular  
57 function, before and after occlusion was significantly lower in STEMI patients compared with HV  
58 controls ( $415\pm 39$  % vs.  $540\pm 39$  %,  $P<0.05$ ).

59  
60 In a linear regression model including age, sex, body mass index (BMI), systolic and diastolic  
61 blood pressure, FMD was found to be independent to MSK1 gene expression ( $\beta=0.436$ ,  $P<0.011$ ),



54 **(Figure 1D)**, MSK 2 gene expression ( $\beta=0.340$ ,  $P<0.01$ ) **(Figure 1E)** and BMI ( $\beta=-0.280$ ,  $P<0.05$ ).  
55 Additionally, the GTN response was found to be independent to MSK2 gene expression ( $\beta=0.377$ ,  
56  $P<0.05$ ) and BMI ( $\beta=-0.315$ ,  $P<0.05$ ). The percentage change in velocity time integral  
57 (microvascular function) was independent of MSK1 gene expression ( $\beta=0.341$ ,  $P<0.05$ ) and MSK2  
58 gene expression ( $\beta=0.354$ ,  $P<0.01$ ), suggesting a role for MSK1/2 in endothelium-dependent  
59 microvascular function.

70

### 71 **MSK1 kinase in endothelial cells**

72 To further validate these observations, we studied MSK1 activation in dermal skin microvascular  
73 endothelial cells. We stimulated endothelial cells *in vitro* with p38 MAPK activator anisomycin.  
74 MSK1 was detected in skin microvascular dermal endothelial cells. Anisomycin activated p38  
75 MAPK and phosphorylated CREB **(Supplementary Figure 1)** and we hypothesised that MSK1/2  
76 kinases may be involved in the development of endothelial dysfunction.

77

### 78 **MSK1/2 KO mice show altered plasma cytokines but similar vascular responses to WT mice** 79 **at study baseline**

80 To determine the role of MSK1/2 in vascular function, we utilised MSK1/2 KO mice and *in vivo*  
81 LDI. This translational approach allowed vascular function testing longitudinally in the same animal  
82 population. Baseline body weights at 16 weeks of age were significantly greater in WT than in  
83 MSK1/2 KO mice ( $28\pm 1g$  VS.  $26\pm 1g$  respectively,  $P<0.01$ ) **(Supplementary Figure 2A)**.  
84 Additionally, they displayed elevations in plasma IL-1 $\alpha$  ( $P<0.01$ ), IL-6 ( $P<0.001$ ), E-selectin  
85 ( $P<0.01$ ) and lower levels of IL-10 ( $P<0.001$ ), when compared against WT mice **(Figure 2A-D)**.  
86 Plasma levels of TNF- $\alpha$  and total plasma cholesterol levels were similar between MSK1/2 KO and  
87 WT control animals **(Figure 2E-G)**. MSK1/2 KO mice had similar vascular responses to WT litter  
88 mates **(Figure 3A)**, suggesting that the degree of systemic inflammation and potential duration did  
89 not alter vascular function. Endothelium-dependent vascular responses are mediated by the

30 bioavailability of nitric oxide (NO), therefore we studied whether MSK1/2 KO mice exhibited  
31 changes in NO bioavailability.

32

### 33 **L-NAME inhibits endothelium dependent vasodilation in MSK1/2 KO mice at baseline**

34 At baseline, administration of the endothelial NO synthase (NOS) inhibitor, L-NAME produced a  
35 significant reduction in the peak endothelial dependent vascular response in MSK1/2 KO and WT  
36 control mice ( $320\pm 56$  to  $257\pm 60$  AU,  $P<0.01$  in WT mice and  $318\pm 60$  to  $243\pm 65$  AU,  $P<0.01$  in  
37 MSK1/2 KO mice). Demonstrating that endothelium-dependent vascular responses were mediated  
38 by NO in MSK1/2 KO and WT mice at baseline.

39

### 40 **MSK1/2 KO animals show endothelial dysfunction and loss of nitric oxide**

41 WT mice on a standard chow diet displayed similar microvascular responses over the study  
42 period, (**Figure 3A**) demonstrating preserved NO-mediated vasodilatation. WT animals fed a  
43 cholesterol diet show attenuated vascular responses, in agreement with our previous studies (28).  
44 MSK1/2 KO mice on a standard chow or cholesterol enriched diet showed significant attenuation  
45 of endothelium-dependent responses over time ( $P<0.001$ ) (**Figure 3A**). MSK1/2 KO on either diet  
46 showed no significant change to L-NAME at study week 12 (chow-fed  $226\pm 18$  AU versus  $251\pm 18$   
47 AU,  $P>0.05$  and cholesterol-fed  $235\pm 19$  AU versus  $237\pm 38$ ,  $P>0.05$ ), indicating diminished NO  
48 bioavailability was responsible for the attenuated vascular responses in MSK1/2 KO mice.

39

### 10 **Maximum and endothelium-independent responses**

11 To better understand maximal vasodilator capacity in the skin microcirculation measurements  
12 using our *in vivo* setup, we utilised localised skin heating to  $44^{\circ}\text{C}$ . We found similar responses  
13 amongst the groups, suggesting that cholesterol feeding in WT and MSK1/2 deficiency in mice  
14 (cholesterol and chow groups) affects endothelial function specifically without affecting generalised  
15 smooth muscle function (**Figure 3B**). Importantly, localised skin heating of the skin

16 microvasculature provides a drug free measurement of vascular function in rodents in combination  
17 with LDI. We confirmed endothelium-independent microvascular responses at study end-point by  
18 iontophoresis of SNP and found that responses were not significantly different amongst the study  
19 groups This suggests localised damage to the endothelium in MSK1/2 KO animals and WT-  
20 cholesterol fed mice (**Figure 3C**).

21

### 22 **Plasma cytokines are altered in MSK1/2 KO mice and correlate with vascular function**

23 At the end of the experiment, plasma levels TNF- $\alpha$ , IL-6 and IL-1 $\alpha$  were significantly greater in  
24 MSK1/2 KO chow-fed and MSK1/2 KO cholesterol-fed mice at study end-point, when compared to  
25 WT-controls on either diet (**Figure 4A-E**).

26

27 Endothelium-dependent microvascular responses and localised skin heating at study baseline  
28 showed no significant correlations with the blood derived parameters including cytokines and  
29 cholesterol. In contrast, a number of significant correlations were observed between blood  
30 markers and endothelium-dependent microvascular responses at study end point. Importantly,  
31 these correlations were not present with SNP iontophoresis or with the response to localised skin  
32 heating. Peak endothelium-dependent responses at study endpoint (24 weeks) significantly  
33 correlated with IL-1 $\alpha$  ( $R^2 = -0.514$ ,  $P < 0.001$ ), IL-6 ( $R^2 = -0.581$ ,  $P < 0.001$ ), IL-10 ( $R^2 = 0.651$ ,  
34  $P < 0.001$ ), TNF- $\alpha$  ( $R^2 = -0.617$ ,  $P < 0.001$ ), and E-selectin ( $R^2 = -0.424$ ,  $P < 0.001$ ) (Figure 4.8). From  
35 the univariate correlations above, these were entered into a stepwise linear regression model.  
36 Independent determinants of endothelium-dependent responses were IL-10 ( $\beta = 0.483$ ,  $P < 0.001$ )  
37 and IL-1 $\alpha$  ( $\beta = -0.286$ ,  $P < 0.001$ ).

38

### 39 **MSK1/2 KO-cholesterol fed mice are more susceptible to dyslipidaemia**

40 MSK1/2 KO-cholesterol fed mice had significant greater dyslipidaemia, when compared to WT-  
41 cholesterol fed mice (**Figure 4F**).

12

### 13 **Body weights**

14 WT-chow (baseline 27±1g VS. week 24 32±1g, P<0.001), WT-cholesterol (baseline 30±1g VS.  
15 week 24 36±1g, P<0.001), KO-chow (baseline 27±1g VS. week 24 32±1g, P<0.001) and KO-  
16 cholesterol (baseline 26±1g VS. week 24 35±1g, P<0.001) fed mice significantly increased in body  
17 weight over the study duration. End-point body weights were significantly greater in cholesterol fed  
18 WT and

19 MSK 1/ 2 KO mice (P<0.001) when compared to control chow fed mice (**Supplementary Figure**  
20 **2B**).

31

### 32 **Preservation of endothelium-dependent responses and nitric oxide activity in MYD88 KO-** 33 **cholesterol fed mice**

34 We have demonstrated that MSK1/2 are activated after TLR stimulation (19). TLR activation  
35 involves the recruitment of MyD88 to initiate cytoplasmic signalling. MyD88 KO mice has been  
36 previously shown to reduce atherosclerotic plaque formation (29, 30). However, the role of MyD88  
37 in endothelial function has not previously been reported *in vivo*. To ascertain whether TLR  
38 activation induces endothelial dysfunction in response to dietary cholesterol, we fed MyD88 KO  
39 mice a cholesterol rich diet. MyD88 KO (27±1g) mice were significantly heavier than WT (25±1g)  
40 animals at study baseline (P<0.01) (**Supplementary Figure 3A**). MyD88 KO-cholesterol fed mice  
41 were resistant to endothelial dysfunction (**Figure 5A/B**). MyD88 KO-cholesterol fed mice had  
42 significantly lower plasma levels of IL-6 and IL-1α when compared with WT-cholesterol control  
43 mice (**Figure 5 C and D**). In agreement with previous reports, (29) we show that MyD88-  
44 cholesterol fed animals display exaggerated dyslipidaemia(**Figure 5 E and F**). This supports the  
45 view that cholesterol feeding in mice induces microvascular dysfunction and systemic cytokine  
46 expression through TLRs-MyD88-MSK1/2. Animals in all groups significantly increased in body  
47 weight over the study duration: WT-chow (baseline 26±1 g VS. week 20 29±1g, P<0.001), WT-

38 cholesterol (baseline  $25\pm 1$ g VS. week 20  $30\pm 1$ g,  $P<0.001$ ) KO-chow (baseline  $27\pm 1$ g VS. week 20  
39  $32\pm 1$ g,  $P<0.05$ ) and KO-cholesterol (baseline  $26\pm 1$ g VS. week 20  $30\pm 1$ g,  $P<0.001$ ) but there were  
70 no differences amongst the groups for body weights at study end point ( $P>0.05$ ) (**Supplementary**  
71 **Figure 3B**).

72

### 73 **The role of MAPKAP 2/3 in vascular dysfunction and plasma cytokine expression**

74 As p38 $\alpha$  activates MAPKAPK2 and 3 in addition to MSK1/2. We investigated the role of  
75 MAPKAPK2 and 3 using MAPKAPK2/3 knockout mice. These two kinases are important  
76 messengers in the inflammation cascade, and their involvement is mainly in regulation of gene  
77 expression (21, 31). MAPKAP 2/3 have shown potential as a therapeutic target in a KO mouse  
78 models, through abrogated cytokine release and less atherosclerotic plaque formation in a  
79 collagen induced rheumatoid arthritis animal model (22, 23)

30

31 We assessed whether MAPKAP 2/3 KO mice were susceptible to endothelial dysfunction using  
32 our *in vivo* model. There were no significant differences for vascular function at study baseline  
33 between WT and MAPKAP 2/3 KO mice for endothelium-dependent vasodilatation (**Figure 6A**) or  
34 maximal vasodilator dilator capacity to localised skin heating. WT ( $27\pm 1$ g) animals were  
35 significantly heavier than KO mice at study baseline ( $23\pm 1$ g) (12 weeks of age) ( $P<0.001$ ).

36

### 37 **Preservation of nitric oxide in MAPKAP 2/3 KO mice in response to dietary cholesterol**

38 MAPKAP 2/3 KO-cholesterol fed mice had similar endothelium-dependent responses to WT-chow  
39 fed mice at study week 8 and 12, suggesting that MAPAKP 2/3 signalling is involved in dietary  
40 cholesterol mediated vascular dysfunction. MAPAKP 2/3 KO-cholesterol fed animals had greater  
41 endothelium-dependent vasodilation at study week 20 measurements when compared with WT-  
42 cholesterol fed mice. However, these observations did not meet statistical significance for multiple  
43 comparisons ( $P>0.05$ ) (**Figure 6A**).

34

35 L-NAME administration to MAPKAP 2/3 KO-cholesterol fed mice at 20 weeks induced significant  
36 attenuation in the peak endothelium-dependent response compared with the response without L-  
37 NAME ( $P < 0.001$ ), demonstrating preservation of NO bioavailability. These data show that TLR-  
38 MyD88-MSK1/2-MAPKAP2/3 activation diminishes NO bioavailability and mediates endothelial  
39 dysfunction.

30

## 01 **Discussion**

02 In this study, we show decreased gene expression of MSK1 and MSK 2 in PBMCs from patients  
03 presenting with STEMI. This finding correlates with attenuated endothelium-dependent  
04 macrovascular (FMD) and microvascular (velocity time integral) function. Endothelial cell express  
05 MSK1 and TLR agonists induce phosphorylation of downstream CREB. In mice, MSK1/2  
06 deficiency caused elevated systemic pro-inflammatory cytokine expression and decreased anti-  
07 inflammatory cytokine expression with significant impairment in endothelium-dependent  
08 vasodilatation. Blood cytokine levels correlated negatively with microvascular function in mice.  
09 Endothelium-dependent skin microvascular responses are dependent on the bioavailability of NO.  
10 Our studies using L-NAME showed that endothelium-dependent responses were, in part,  
11 mediated via the actions of NO, and therefore, a reduction in endothelium-dependent responses in  
12 MSK1/2 deficient mice was possibly mediated via loss of NO bioavailability. In contrast, WT  
13 animals fed a normal chow diet over the 24-week study period maintained normal plasma lipids,  
14 showed no significant changes in basal levels of inflammatory markers and had preservation of  
15 endothelium-dependent vascular responses. Generalised vascular function, tested by  
16 iontophoresis of the endothelium-independent vasodilator SNP and maximum vasodilator capacity  
17 to localised skin heating was not significantly different amongst the groups, suggesting that early  
18 elevation in pro-inflammatory cytokines was affecting vascular function specifically at the level of  
19 the endothelium. These data suggest a possible functional role for MSK1/2 in the development  
20 and progression of CVD through an interaction between regulation of inflammatory cytokines and  
21 endothelial dysfunction. These data support clinical studies, which have linked blood cytokine  
22 levels to the development and progression of CVD (5-7).

23

24 Endothelial cells are not traditionally characterised as components of the innate immune system  
25 but they express TLRs, similar to monocytes (9), macrophages (29, 32) and neutrophils(33), which  
26 are implicated in the development, progression and regression of vascular disease. Endothelial

27 cells interface with circulating blood and thus alterations in systemic cytokine expression and/or  
28 changes in plasma lipids can influence endothelial cell biology. Here we highlight, that endothelial  
29 cells show activation of MSK1/2 in response to TLR agonists. TLR activation is important in the  
30 initiation of pro-inflammatory responses in immune cells and TLR deficiency attenuates the  
31 progression of atherosclerotic plaques in hyperlipidaemic mice (29). TLR activation can be initiated  
32 by stimuli, which are risk factors for CVD, including oxidised low density lipoproteins. TLR  
33 signalling is complex and involves recruitment of MyD88, which enables transcytoplasmic  
34 signalling and activation of inflammatory cascades via MAPKs, p38, and NF- $\kappa$ B. We demonstrate  
35 here that MyD88 is necessary for endothelial cell dysfunction in the face of hypercholesterolemia  
36 *in vivo*. Similarly, TLR-MyD88 effects have been reported in a model of atherosclerosis (29),  
37 obesity (30) and diabetes (34). We believe this is the first description of TLR-MyD88-MSK1/ 2  
38 kinases in the initiation of early vascular disease in an *in vivo* rodent model relevant to human  
39 microvascular impairment and CVD.

40

41 Baseline endothelial-dependent responses were dependent on NO in both WT and MSK1/2 KO  
42 mice as shown by the significant reduction following pre-treatment with L-NAME. At study  
43 baseline, although we found elevations in pro-inflammatory markers in MSK1/2 KO mice  
44 compared with WT mice (increased IL-1 $\alpha$ , IL-6, E-selectin and reduced IL-10), we did not see any  
45 significant differences in endothelial-dependent responses, perhaps indicating that the relative  
46 difference and potential duration of change in cytokine levels was not sufficient enough to impact  
47 significantly on vascular function at that time point. The difference in inflammatory cytokines  
48 between WT and KO mice at baseline may be mediated by environmental factors e.g., exposure  
49 to infectious agents.

50

51 Mice were initially bred and maintained in a barrier facility and subsequently rehoused for vascular  
52 testing in a conventional unit, at which they could have been exposed to additional micro-



53 organisms. The onset of CVD and induction of pro-inflammatory gene expression in immune  
54 compromised animals has previously been reported in non-pathogen free conditions when animals  
55 are challenged with high cholesterol feeding (35). Previous findings show that high cholesterol  
56 feeding induces greater adverse changes in pro-inflammatory cytokines (28), with resultant  
57 endothelial dysfunction in WT mice (36). Interestingly, we found that MSK1/2 KO mice fed a  
58 normal chow diet over 24 weeks also displayed elevations in pro-inflammatory cytokines and  
59 diminished endothelial-dependent responses. This shows that in the absence of a major CVD risk  
60 factor i.e. elevated plasma cholesterol, mice lacking MSK1/2 still can develop significant  
61 endothelial dysfunction, to a degree similar to that seen with cholesterol feeding. The exact  
62 mechanism for this dysfunction requires further scrutiny. Interestingly, despite a greater reduction  
63 in NO bioavailability in MSK1/2 KO mice, endothelium-dependent responses in the presence of L-  
64 NAME were not as low as responses in WT cholesterol-fed mice post L-NAME. It is possible that  
65 the higher level of perfusion in the MSK1/2 KO mice might be related to a compensatory increase  
66 in ACh-induced production of endothelium-derived hyperpolarising factor (37).

57

58 We found significant correlations between microvascular responses and levels of cytokines at 24  
59 weeks, which demonstrates that our methodology for assessment of microvascular function in the  
70 skin is sensitive and reflective of systemic inflammation and similar to what we have reported in  
71 patients (26). IL-10 proved to be the strongest independent determinant of endothelium-dependent  
72 response in a multivariate regression model with IL-1 $\alpha$  also proving to be an independent  
73 determinant. IL-1 $\alpha$  is unregulated in cholesterol fed mice and can stimulate atherosclerosis (28,  
74 38). IL-1 $\alpha$  is synthesised by activated endothelial cells and is released early in the atherosclerotic  
75 process and mediates the expression of cell adhesion molecules responsible for the capture,  
76 rolling and subsequent transmigration of immune cells into the sub-endothelial space (39). IL-1 $\alpha$   
77 levels are up regulated in cholesterol fed animals. These regulatory roles of IL-1 are associated  
78 with a number of physiological events including macrophage activation, endothelial proliferation

79 (40), myocardial cell damage and endothelial dysfunction through increased oxidative stress and  
30 inflammation (41, 42). IL-6 has been linked to an increased risk of adverse cardiovascular events  
31 (43, 44) and can be synthesized by a number of cells including macrophages. IL-6 inhibits  
32 endothelial NOS (eNOS) activation and attenuates vasodilation by increasing the half-life of  
33 caveolin-1, resulting in more eNOS binding, leading to reduced bioavailability of NO (45). Thus,  
34 the predisposition of MSK1/ 2 KO mice to produce increased levels of IL-6 may directly mediate  
35 the observed endothelial dysfunction through altered eNOS signalling. IL-10 has a potential  
36 protective role in atherosclerosis and can be produced by macrophages and inhibits pro-  
37 inflammatory cytokine expression through a JAK/STAT3 dependent pathway (46). Ananieva *et. al.*  
38 (19) reported that the increased production of IL-6, and to a lesser extent TNF, was dependent on  
39 the ability of MSKs to regulate IL-10 production. IL-10 KO mouse aortas display significantly  
40 blunted endothelium-dependent responses, which were found to be mediated by a reduction in  
41 eNOS expression (47). Exogenous IL-10 treatment prevents intimal hyperplasia in response to  
42 carotid injury in otherwise healthy mice (48). IL-10 is anti-atherogenic and enhances uptake and  
43 efflux of cholesterol, lowering levels of cell death and the progression of atherosclerotic lesions  
44 (49).

35  
36 Taken together, the increased levels of IL-1 $\alpha$ , IL-6 and TNF- $\alpha$  in MSK1/2 KO mice could explain  
37 observed endothelial-dysfunction in this study, although the mechanisms of diminished NO  
38 bioavailability may be multi-modal and requires further scrutiny. It has previously been reported  
39 that MSK1/2 KO mice have decreased production of IL-1Ra (17). IL-1Ra KO mice display a  
40 significant elevation in plasma cholesterol due to impaired cholesterol efflux through altered  
41 conversion of hepatic cholesterol to bile acids. This is mediated by reduced expression of 7 $\alpha$ -  
42 hydroxylase (CY7A1) the rate limiting step in bile acid synthesis (50). MSK1/ 2 KO mice require  
43 further study to assess the exact mechanism of altered cholesterol homeostasis and the resultant  
44 impact on systemic cytokine expression and endothelial function.

35

## 36 **Limitations**

37 Our STEMI patients were recruited to the study varying in 12-100 hours post PCI and there was a  
38 bias towards male patients

39

## 10 **Conclusions**

11 In conclusion, we have shown that lack of MSK1/2 might be contributing to the inflammatory  
12 response following STEMI, and have used an *in vivo* model to examine longitudinal changes in the  
13 skin microcirculation of WT and KO mice prone to inflammation. MSK1/2 plays an important role in  
14 limiting pro-inflammatory signalling downstream of TLRs, and here we show that deletion of  
15 MSK1/2 produces a marked inflammatory state with consequent early endothelial dysfunction,  
16 reduced NO bioavailability and increased atherosclerotic burden. Targeting the MSK1/2 pathway  
17 with agents that selectively activate MSK1 and MSK 2 might provide a useful therapeutic option for  
18 combating inflammation-induced endothelial dysfunction and atherosclerosis.

19

## 20 **Materials and Methods**

### 21 **Human cohort of ST-elevation myocardial Infarction (STEMI) patients**

22 We recruited 35 patients who were admitted to hospital with STEMI and underwent percutaneous  
23 coronary intervention (PCI) at Ninewells Hospital Coronary Care Unit. Patients provided written,  
24 informed consent for collection of bloods for the isolation of PBMCs and for endothelial function  
25 testing within 12-100 hours post-PCI investigation conformed to the principles outlined in the  
26 Declaration of Helsinki and local ethical approval was granted by review boards at the University  
27 of Dundee. A further 28 age-matched healthy volunteers were recruited as controls. Exclusion  
28 criteria were <18 years of age, unable to give written consent and undergoing current cancer  
29 treatments. Additional exclusion criteria for healthy volunteers included medical history of vascular  
30 diseases such as peripheral arterial disease and stroke, hypertension and haematological  
31 conditions such as hypercoagulability and deep venous thrombosis. A sample size of 40 subjects  
32 in each group was projected to provide >90% power at a 5% level of significance to detect a 15%  
33 difference in gene expression between groups post-PCI and at least 90% power and 5%  
34 significance to detect a 2% difference in FMD.

### 35 36 **Assessment of endothelial function in humans - Flow mediated dilatation**

37 Endothelial function was assessed by measuring flow-mediated dilatation (FMD) of the brachial  
38 artery using an 8-15 MHz linear array ultrasound probe (Sequoia 512, Siemens, Camberley, UK)  
39 as described previously (51-53). In addition, we assessed the endothelium-independent response  
40 by following administration of 0.4 mg sublingual glyceryl trinitrate (GTN). Additionally, for  
41 assessing microvascular function, we obtained blood flow velocity measurements using Doppler  
42 ultrasound at baseline and after 5 minutes of upper arm arterial occlusion as described previously  
43 (54).

### 44 45 **Isolation of peripheral blood mononuclear cells (PBMCs) RNA**

16 PBMCs were isolated from whole blood using density gradient centrifugation over Ficoll-Paque  
17 (GE-Health Care Life Sciences). PBMCs were stored in foetal bovine serum (FBS) and dimethyl  
18 sulphide (DMSO) (10%) and stored at -80°C. RNA was isolated from PBMCs using the Trizol  
19 method as previously described.

50

### 51 **TaqMan RT-qPCR**

52 Real-Time PCR was performed using TaqMan gene expression assay probes from ThermoFisher  
53 (Hs01046591\_m1 (MSK1), Hs01071879\_m1 (MSK2) and Hs01060665\_g1 (ACTINB) and TaqMan  
54 2x Universal PCR Master mix (Applied Biosystems) on a QuantStudio™ 7 Flex qPCR machine.  
55 (Thermo Fischer Scientific Inc).

56

### 57 **Mouse models**

58 All experiments were performed under UK Home Office Licences and conducted according  
59 to the Animals Scientific Procedures Act 1986 (UK) and directive 2010/63/EU of the  
60 European Parliament guidelines on the protection of animals used for scientific purposes. All  
61 experiments were approved by the Institutional Animal Welfare and Ethical Review Body. All  
62 animals were euthanised by cervical dislocation in accordance with local, national UK and EU  
63 guidelines.

64 All mice were male and aged-matched to WT controls. WT and MSK1/2 double KO (55), MyD88  
65 KO (56) and MAPKAP 2/3 double KO mice (21) were obtained from breeding facilities at the  
66 University of Dundee.

57

### 58 **Animal husbandry and group allocation**

59 Adult (10-16 weeks of age) mice were housed in groups of up to six. Diets consisted of standard  
60 rodent chow (Special Diets Services (SDS): Rat & Mouse diet number 1 or 3, United Kingdom)  
61 and sterilised distilled water fed ad libitum, unless otherwise stated. Animals were transferred from

72 a barrier breeding facility to the experimental facility (in which the necessary equipment was  
73 installed) at least one week before vascular function testing, to allow acclimation and to avoid  
74 stress. Animals were randomly allocated into four groups: WT control mice were fed a normal  
75 rodent chow WT mice on a cholesterol diet (TD.01383 diet, Harlan-Teklad; 18% protein rodent  
76 chow with added cholesterol 2% by weight) and KO mice on normal rodent chow and a cholesterol  
77 diet as detailed above. Researchers were blinded to genotypes in the group allocations during  
78 vascular assessments for the study duration.

79

### 30 **Assessment of endothelium-dependent responses**

31 Skin microvascular responses were measured longitudinally in the same animals at 4 week  
32 intervals following baseline measurements using laser Doppler imaging (LDI) as described  
33 previously (27, 28). Animals were anaesthetized using 5% Isoflurane (Abbot Laboratories) in  
34 oxygen (2 litre / minute), which was delivered using a standard Boyle's Apparatus and maintained  
35 by delivering 1.5% - 2% Isoflurane via a nose cone for the duration of the procedure every up to  
36 every four weeks for longitudinal microvascular assessment. Iontophoresis chambers were initially  
37 filled with ~2ml of 1% solution of the  $\alpha_1$ -adrenergic receptor agonist phenylephrine (PE) (Sigma-  
38 Aldrich). Following constriction, PE was washed out of the chamber with deionized water and  
39 replaced with a 2% solution of the endothelium-dependent vasodilator acetylcholine (ACh) (Sigma-  
40 Aldrich). ACh was iontophoresed for 10 minutes using an anodal current of 100 $\mu$ A and the  
41 maximum vasodilator response measured by LDI.

32

### 33 **Role of nitric oxide in endothelium-dependent responses**

34 At baseline, assessment of microvascular responses to ACh were repeated in a separate group of  
35 WT and MSK1/2 KO mice (n = 8 in each group) following pre-treatment with the non-selective  
36 inhibitor of nitric oxide synthase (NOS), N (G)-nitro-L-arginine methyl ester hydrochloride (L-  
37 NAME, Sigma Chemicals). These experiments explored the importance of NO in endothelium-

38 dependent dilatation in our model of inflammation. L-NAME was administered by intraperitoneal  
39 injections (i.p.) (20 mg/kg in deionised water).

40

### 41 **Assessment of endothelium-independent responses**

42 Following pre-constriction with PE, a 2% solution of sodium nitroprusside (SNP) (Sigma-Aldrich)  
43 was iontophoresed on the opposite flank of the animal using a 100 $\mu$ A cathodal current for 10  
44 minutes to test endothelium-independent vasodilation. To reduce the amount of time that each  
45 animal was under general anaesthetic and to limit the amount of drug exposure, responses to  
46 SNP were only measured at the end point of the study.

47

### 48 **Maximum vasodilator response to localised skin heating**

49 A skin heating probe (SH02™ Skin Heating Unit and SHP3 probe, Moor Instruments) with a total  
10 surface area of 3.2cm<sup>2</sup> was attached to the flank using double sided adhesive rings. Baseline  
11 measurements of skin perfusion were taken for 5 minutes, followed by localised heating of the skin  
12 at a rate of 1°C/minute until a maximum temperature of 44°C was achieved. This was maintained  
13 for 10 minutes and the maximum vasodilator response was measured.

14

### 15 **Blood sampling**

16 Blood was collected by tail bleeds at baseline and by cardiac puncture at study end point into  
17 heparinised microtubes (BD Microtainer™ Lithium Heparin) to produce plasma by and  
18 centrifugation. Plasma was decanted and stored at -80°C until analysed.

19

### 20 **Plasma cholesterol**

21 Total cholesterol was measured using a colorimetric assay (Biovision, catalog#: K603-100) as  
22 detailed in the manufacturer's instructions or high-density lipoprotein (HDL) and low-density/ very

23 low-density lipoproteins (LDL/vLDL) fractions were quantified by using a colour metric assay  
24 (Abcam, Product code: ab655390).

25

## 26 **Cytokine analysis**

27 Plasma was analysed using Bio-Plex® Precision Prokits™ from BIO-RAD laboratories 24 for IL-  
28 1 $\alpha$ , IL-6, IL-10, TNF- $\alpha$ , E-selectin as detailed in the manufacturer's instructions.

29

## 30 **Western blotting**

31 C57BL/6 mouse primary dermal microvascular endothelial cells (Cell Biologics, Illinois) were  
32 seeded into tissue culture plates at equal densities. Cells were stimulated with p38/ERK activator:  
33 Anisomycin 10  $\mu$ g / mL as indicated. Cells were pre-treated for 1 hour with inhibitors prior to  
34 stimulation. Inhibitors were purchased in-house from the Division of Signal Transduction Therapy  
35 (DSTT), University of Dundee and included the ERK inhibitor PD184352 (10  $\mu$ M), p38 inhibitor VX-  
36 745 (1  $\mu$ M), MSK1/2 inhibitor SB747581A (10  $\mu$ M), and MK2 inhibitor PF36444022 (10  $\mu$ M).

37 After stimulations cells were lysed (50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1 mM  
38 sodium orthovanadate, 50 mM sodium fluoride, 1 mM sodium pyrophosphate, 10 mM sodium  
39 glycerophosphate, 0.27 M sucrose, 1% (vol/vol) Triton X-100 with Leupeptin 5 mg / mL, Aprotinin  
40 5mg/mL, PMSF 200mM, 0.1%  $\beta$ -mercapto-ethanol and bromophenol blue), boiled for 10 minutes  
41 and passed through a 25G syringe needle. Equal volumes of all lysates were separated on  
42 SDS/PAGE with a 10% polyacrylamide gel. Gels were transferred onto nitrocellulose membrane  
43 (Amersham) and blocked in 5% milk-TBS-T for 15 minutes. Subsequently, membranes were  
44 probed with primary antibodies overnight at 4°C at 1:1000 for: phosphor-CREB at ser133,  
45 phospho-p38 at Thr180/Tyr182, p38-MAPK, phospho-p44/42 MAPK (Erk1/2) at Thr202/Tyr204,  
46 p44/42 MAPK (Erk1/2), phosphor-MAPKAPK-2 at Thr344, MAPKAPK-2, phosphor-HSP27 at Ser  
47 83 (all from Cell Signalling Technologies). In-house anti-sheep MSK1 at 5  $\mu$ g / mL was from the



48 DSTT. Membranes were probed with appropriate secondary antibodies (anti-sheep or anti-rabbit,  
49 ThermoFischer) and visualised via ECL (Amersham) on a Licor<sup>®</sup> Imaging System.

50

### 51 **Statistical analysis**

52 Statistical analysis was performed on SPSS statistical package (v22/24/26) or GraphPad Prism.

53 All data are expressed as group means  $\pm$  SE.

54 Two group comparisons were compared using two tailed unpaired or paired students T-tests. Two  
55 or more group comparisons were made by one or two way ANOVA with post-hoc Bonferroni  
56 correction. Associations were assessed by Pearson's correlation. Multiple linear regression was  
57 performed with dependent variables (age, sex, BMI, systolic blood pressure and diastolic blood  
58 pressure).  $P < 0.05$  were regarded as significant.

59

### 50 **Study Approval**

51 Patients provided written, informed consent for investigations, which conformed to the principles  
52 outlined in the Declaration of Helsinki and local ethical approval was granted by review boards at  
53 the University of Dundee.

54 **Author Contributions**

55 NA undertook all in vivo experimentation, designed and conceived the study with FK and JSCA.

56 NA, FK, KRFK, CF, CM, MH, CCL, IM, UB were involved with the clinical studies.

57 NA, CF MSH, KR, JJFB, CCL, IM, UB, JSCA and FK were involved with the analysis and  
58 interpretation of the data. All authors helped in preparation of the manuscript, read the final version  
59 of the manuscript and approved its submission.

70

71 **Acknowledgments**

72 This work was supported by the Medical Research Council, TENOVUS Scotland, and the  
73 Anonymous Trust, University of Dundee. We thank Professor Sir Philip Cohen for facilitating this  
74 collaboration.

75

76

77 **Table 1:** STEMI patient and healthy volunteer characteristics

78

79 **Supplemental Materials**

30 **Supplement 1**

31 Detection of MSK in dermal microvascular endothelial cells

32

33 **Supplement 2**

34 Body weight of MSK1/2 knock-out and wild-

35

36 **Supplement 3**


37 Body weight of MyD88 knock-out and wild-type

38


39

30 **FIGURES**

31 **Figure 1. MSK1/2 expression and endothelial function are attenuated following acute**  
32 **myocardial infarction.** Relative MSK1 (A) and MSK2 (B) gene expression in peripheral blood  
33 mononuclear cells from healthy volunteers and patients presenting with ST-segment elevation  
34 acute myocardial infarction (STEMI). (C) Flow mediated dilation (FMD) (% cuff change) in STEMI  
35 patients and healthy volunteers. Pearson's Correlation between FMD response and MSK1 (E) /  
36 MSK2 (F) gene expression. Healthy volunteers N= 28 STEMI N= 34. Values are group mean±SE.  
37 A-C Unpaired T-tests. \*\*\*P<0.001. E/F Person's correlation, dotted line represents 95%  
38 confidence interval.




30 **Figure 2. Plasma cytokine and cholesterol measurements in MSK1/2 knock-out and**  
31 **wildtype mice.** (N=36) wild-type (WT) and MSK1/2 knock-out (KO) (N=38). Plasma levels of  
32 Inflammatory markers in mice (pg / mL) at study baseline: (A) IL-1 $\alpha$ , (B) IL-6, (C) sE-Selectin, (D)  
33 IL-10, (E) TNF- $\alpha$ , (F) total plasma cholesterol (mmol / L). Values are group mean $\pm$ SE. A-F  
34 Unpaired T-tests. \*\*P<0.01, \*\*\*P<0.001.




35

36

37 **Figure 3. Microvascular responses in MSK1/2 knockout and wild-type mice.** (A) endothelial-  
38 dependent microvascular responses in arbitrary units (AU) over 24 weeks and (B) localised 44°C  
39 heating (over 24 weeks) and terminal endothelial-independent (C) in wild-type (WT)-chow (N=19),  
40 WT-cholesterol (n=19), MSK1/2 knock-out (KO)-chow (N=18) and MSK1/2 KO-cholesterol (N=18)  
41 fed animals. Longitudinal changes were analysed by ANOVA for repeated measures followed by  
42 post-hoc Bonferroni correction. Values are group means±SE.  
43 \*\*\*comparing responses between WT-chow ,WT-cholesterol, MSK1/2, KO-chow and MSK1/2 KO-  
44 cholesterol fed mice.  
45 # and ## comparing responses between MSK1/2 KO-cholesterol, WT-cholesterol and MSK1/2  
46 KO-chow fed mice.




18 **Figure 4. Plasma cytokine and cholesterol measurements in MSK1/2 knockout and wild-**  
19 **type mice.** Wild-type (WT)-chow (N=19), WT-cholesterol (N=19), MSK1/2 knock-out (KO)-chow  
20 (N=18) and MSK1/2 KO-cholesterol (N=18) fed mice (pg/mL). **(A)** IL-1 $\alpha$ , **(B)** IL-6, **(C)** IL-10, **(D)**  
21 TNF- $\alpha$ , **(E)** sE-Selectin, **(F)** total plasma cholesterol (mmol / L). Differences between genotype  
22 groups were tested using two way-ANOVA followed by post-hoc Bonferroni correction. Between  
23 genotype difference for influence of diet were assessed by unpaired T-tests. Values are group  
24 means $\pm$ SE. \*\*P<0.01, \*\*\*P<0.001.



25

26


27 **Figure 5. Microvascular responses in MyD88 knockout and wild-type mice.** (A) Endothelium-  
28 dependent microvascular responses in arbitrary units (AU) over 20 weeks and (B) terminal  
29 endothelium-independent in wild-type (WT)-chow (N =9), WT-cholesterol (N =15), MyD88 knock-  
30 out (KO)-chow (N =9) and MyD88 KO-cholesterol (N =8) fed animals. Longitudinal changes were  
31 analysed by ANOVA for repeated measures followed by post-hoc Bonferroni correction. **A-B**  
32 \*P<0.05, \*\*\*P<0.001 comparing genotypes, #P<0.05, ###P<0.01 comparing diet. Plasma cytokines  
33 (pg / mL) (C) IL-1 $\alpha$ , (D) IL-6 and (E) IL-10 WT-chow (N =10), WT-cholesterol (N=10), MyD88 KO-  
34 chow (N=10) and MyD88 KO-cholesterol fed (N=10) mice. Plasma measurements of (F) low  
35 density lipoproteins and very low density lipoproteins (LDL/vLDL) and high density lipoproteins  
36 (HDL) in the plasma of WT-chow (N=10), WT-cholesterol (N=11), MyD88 KO-chow (N=8) and  
37 MyD88 KO-cholesterol fed mice (N=8) (mg / dL). **C-E** two-way ANOVA. Values are group  
38 means $\pm$ SE. \*\*P<0.01, \*\*\*P<0.001.





10 **Figure 6. Microvascular responses in MAPKAP2/3 knockout and wild-type mice.**  
11 **(A)** Endothelium-dependent microvascular responses in arbitrary units (AU) over 20 weeks and  
12 **(B)** terminal endothelium-independent in wild-type (WT)-chow (N=17), WT-cholesterol (N=12),  
13 MAPKAP knock-out (KO)-chow (N=11) and MAPKAP KO-cholesterol (N=13) fed animals.  
14 Longitudinal changes were analysed by ANOVA for repeated measures followed by post-hoc  
15 Bonferroni correction. **A-B** \*\*P<0.01 comparing genotypes, #P<0.05, ##P<0.01 comparing diet  
16 Plasma cytokines (pg / mL) **(C)** IL-1 $\alpha$ , **(D)** IL-6 and **(E)** IL-10 in WT-chow (N=10), WT-cholesterol  
17 (N=10), MAPKAP KO-chow (n =10) and MAPKAPKO-cholesterol fed (N=10) mice. Plasma  
18 measurements of **(F)** low density lipoproteins and very low density lipoproteins (LDL/vLDL) and  
19 **(G)** High density lipoproteins (HDL) in the plasma of WT-chow (N =10), WT-cholesterol (N =9),  
20 MAPKAP KO-chow (N=9) and MAPKAP KO-cholesterol fed mice (N=10) (mg / dL). **C-G** two-way  
21 ANOVA Values are group means $\pm$ SE \*\*\*P<0.001.  
22

23



55 **References**

- 56 1. Rahman K, and Fisher EA. Insights From Pre-Clinical and Clinical Studies on the Role of Innate Inflammation  
57 in Atherosclerosis Regression. *Front Cardiovasc Med.* 2018;5(32):32.
- 58 2. Poduri A, Bahl A, Talwar KK, and Khullar M. Proteomic analysis of circulating human monocytes in coronary  
59 artery disease. *Mol Cell Biochem.* 2012;360(1-2):181-8.
- 50 3. Steppich BA, Demetz G, Schulz S, von Wedel J, Pogatsa-Murray G, Braun SL, et al. Effects of G-CSF on  
51 systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction.  
52 *Thrombosis research.* 127(2):119-21.
- 53 4. Davignon J, and Ganz P. Role of endothelial dysfunction in atherosclerosis. *Circulation.* 2004;109(23 Suppl  
54 1):III27-32.
- 55 5. Howard-Alpe GM, Sear JW, and Foex P. Methods of detecting atherosclerosis in non-cardiac surgical  
56 patients; the role of biochemical markers. *Br J Anaesth.* 2006;97(6):758-69.
- 57 6. Pan JP, Liu TY, Chiang SC, Lin YK, Chou CY, Chan WL, et al. The value of plasma levels of tumor necrosis  
58 factor-alpha and interleukin-6 in predicting the severity and prognosis in patients with congestive heart  
59 failure. *J Chin Med Assoc.* 2004;67(5):222-8.
- 70 7. Ridker PM, Hennekens CH, Buring JE, and Rifai N. C-reactive protein and other markers of inflammation in  
71 the prediction of cardiovascular disease in women. *N Engl J Med.* 2000;342(12):836-43.
- 72 8. Tobias PS, and Curtiss LK. Toll-like receptors in atherosclerosis. *Biochem Soc Trans.* 2007;35(Pt 6):1453-5.
- 73 9. Ruparelia N, Godec J, Lee R, Chai JT, Dall'Armellina E, McAndrew D, et al. Acute myocardial infarction  
74 activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment,  
75 and identified through conserved transcriptional responses in mice and humans. *Eur Heart J.*  
76 2015;36(29):1923-34.
- 77 10. Menghini R, Campia U, Tesauro M, Marino A, Rovella V, Rodia G, et al. Toll-Like Receptor 4 Mediates  
78 Endothelial Cell Activation Through NF- $\kappa$ B but Is Not Associated with Endothelial Dysfunction in Patients with  
79 Rheumatoid Arthritis. *PLoS one.* 2014;9(6):e99053.

- 30 11. Salvador B, Arranz A, Francisco S, Cordoba L, Punzon C, Llamas MA, et al. Modulation of endothelial function  
31 by Toll like receptors. *Pharmacological research : the official journal of the Italian Pharmacological Society.*  
32 2016;108:46-56.
- 33 12. Seeger FH, Sedding D, Langheinrich AC, Haendeler J, Zeiher AM, and Dimmeler S. Inhibition of the p38 MAP  
34 kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic  
35 disease progression. *Basic Res Cardiol.* 2010;105(3):389-97.
- 36 13. Kyoj S, Otani H, Matsuhisa S, Akita Y, Tatsumi K, Enoki C, et al. Opposing effect of p38 MAP kinase and JNK  
37 inhibitors on the development of heart failure in the cardiomyopathic hamster. *Cardiovascular research.*  
38 2006;69(4):888-98.
- 39 14. O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, et al. Effect of Losmapimod on  
40 Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical  
41 TrialEffect of Losmapimod on Cardiovascular Outcomes in Patients With Acute MIEffect of Losmapimod on  
42 Cardiovascular Outcomes in Patients With Acute MI. *JAMA.* 2016;315(15):1591-9.
- 43 15. Arthur JS, and Ley SC. Mitogen-activated protein kinases in innate immunity. *Nature reviews Immunology.*  
44 2013;13(9):679-92.
- 45 16. Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, et al. The kinase p38 alpha serves cell type-specific  
46 inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. *Nat*  
47 *Immunol.* 2008;9(9):1019-27.
- 48 17. Darragh J, Ananieva O, Courtney A, Elcombe S, and Arthur JS. MSK1 regulates the transcription of IL-1ra in  
49 response to TLR activation in macrophages. *Biochem J.* 2010;425(3):595-602.
- 50 18. Arthur JS. MSK activation and physiological roles. *Front Biosci.* 2008;13:5866-79.
- 51 19. Ananieva O, Darragh J, Johansen C, Carr JM, McIlrath J, Park JM, et al. The kinases MSK1 and MSK2 act as  
52 negative regulators of Toll-like receptor signaling. *Nat Immunol.* 2008;9(9):1028-36.
- 53 20. Wang X, and Liu Y. Regulation of innate immune response by MAP kinase phosphatase-1. *Cellular signalling.*  
54 2007;19(7):1372-82.

- 35 21. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti E, Milarski K, et al. The mitogen-activated protein  
36 kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor  
37 biosynthesis and stabilization of p38 MAPK. *Mol Cell Biol.* 2007;27(1):170-81.
- 38 22. Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, and Telliez JB. MAPKAP kinase 2-deficient mice are  
39 resistant to collagen-induced arthritis. *J Immunol.* 2006;177(3):1913-7.
- 10 23. Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, and Bavendiek U. Systemic deficiency of the MAP  
11 kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. *Circulation research.*  
12 2007;101(11):1104-12.
- 13 24. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, and Camici PG. Relation between Myocardial Blood  
14 Flow and the Severity of Coronary-Artery Stenosis. *New England Journal of Medicine.* 1994;330(25):1782-8.
- 15 25. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, et al. Circulating Microparticles From  
16 Patients With Myocardial Infarction Cause Endothelial Dysfunction. *Circulation.* 2001;104(22):2649-52.
- 17 26. Galarraga B, Khan F, Kumar P, Pullar T, and Belch JJ. C-reactive protein: the underlying cause of  
18 microvascular dysfunction in rheumatoid arthritis. *Rheumatology (Oxford).* 2008;47(12):1780-4.
- 19 27. Akbar N, Nanda S, Belch J, Cohen P, and Khan F. An important role for A20-binding inhibitor of nuclear  
20 factor-kB-1 (ABIN1) in inflammation-mediated endothelial dysfunction: an in vivo study in ABIN1 (D485N)  
21 mice. *Arthritis Res Ther.* 2015;17(1):22.
- 22 28. Belch JJ, Akbar N, Alapati V, Petrie J, Arthur S, and Khan F. Longitudinal assessment of endothelial function in  
23 the microvasculature of mice in-vivo. *Microvasc Res.* 2013;85:86-92.
- 24 29. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in  
25 MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways.  
26 *Nature medicine.* 2004;10(4):416-21.
- 27 30. Yu M, Zhou H, Zhao J, Xiao N, Roychowdhury S, Schmitt D, et al. MyD88-dependent interplay between  
28 myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. *J*  
29 *Exp Med.* 2014;211(5):887-907.

- 30 31. Ronkina N, Menon MB, Schwermann J, Tiedje C, Hitti E, Kotlyarov A, et al. MAPKAP kinases MK2 and MK3 in  
31 inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin.  
32 *Biochem Pharmacol.* 2010;80(12):1915-20.
- 33 32. Sun Y, Ishibashi M, Seimon T, Lee M, Sharma SM, Fitzgerald KA, et al. Free cholesterol accumulation in  
34 macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces  
35 cathepsin K. *Circulation research.* 2009;104(4):455-65.
- 36 33. Feng Y, Zhao H, Xu X, Buys ES, Raheer MJ, Bopassa JC, et al. Innate immune adaptor MyD88 mediates  
37 neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. *American journal of*  
38 *physiology Heart and circulatory physiology.* 2008;295(3):H1311-H8.
- 39 34. Hosoi T, Yokoyama S, Matsuo S, Akira S, and Ozawa K. Myeloid differentiation factor 88 (MyD88)-deficiency  
40 increases risk of diabetes in mice. *PloS one.* 2010;5(9).
- 41 35. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10 in  
42 atherosclerosis. *Circulation research.* 1999;85(8):e17-24.
- 43 36. Meyrelles SS, Peotta VA, Pereira TM, and Vasquez EC. Endothelial dysfunction in the apolipoprotein E-  
44 deficient mouse: insights into the influence of diet, gender and aging. *Lipids Health Dis.* 2011;10:211.
- 45 37. Verma S, Buchanan MR, and Anderson TJ. Endothelial function testing as a biomarker of vascular disease.  
46 *Circulation.* 2003;108(17):2054-9.
- 47 38. Freigang S, Ampenberger F, Weiss A, Kanneganti T-D, Iwakura Y, Hersberger M, et al. Fatty acid-induced  
48 mitochondrial uncoupling elicits inflammasome-independent IL-1 $\alpha$  and sterile vascular inflammation in  
49 atherosclerosis. *Nat Immunol.* 2013;14:1045.
- 50 39. Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, et al. Hypoxia-mediated induction of  
51 endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion  
52 molecules on the vessel surface. *The Journal of clinical investigation.* 1992;90(6):2333-9.
- 53 40. Hoge M, and Amar S. Role of interleukin-1 in bacterial atherogenesis. *Timely Top Med Cardiovasc Dis.*  
54 2007;11:E5.

- 55 41. Chi H, Messas E, Levine RA, Graves DT, and Amar S. Interleukin-1 receptor signaling mediates atherosclerosis  
56 associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model:  
57 pharmacotherapeutic implications. *Circulation*. 2004;110(12):1678-85.
- 58 42. Chamberlain J, Evans D, King A, Dewberry R, Dower S, Crossman D, et al. Interleukin-1beta and signaling of  
59 interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. *The*  
60 *American journal of pathology*. 2006;168(4):1396-403.
- 61 43. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, et al. Plasma interleukin-6 and tumor necrosis  
62 factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. *Hypertens Res*.  
63 2007;30(6):541-8.
- 64 44. Ridker PM, Rifai N, Stampfer MJ, and Hennekens CH. Plasma Concentration of Interleukin-6 and the Risk of  
65 Future Myocardial Infarction Among Apparently Healthy Men. *Circulation*. 2000;101(15):1767-72.
- 66 45. Hung MJ, Cherng WJ, Hung MY, Wu HT, and Pang JH. Interleukin-6 inhibits endothelial nitric oxide synthase  
67 activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular  
68 endothelial cells. *J Hypertens*.28(5):940-51.
- 69 46. Pattison MJ, Mackenzie KF, and Arthur JS. Inhibition of JAKs in macrophages increases lipopolysaccharide-  
70 induced cytokine production by blocking IL-10-mediated feedback. *J Immunol*. 2012;189(6):2784-92.
- 71 47. Zemse SM, Chiao CW, Hilgers RH, and Webb RC. Interleukin-10 inhibits the in vivo and in vitro adverse  
72 effects of TNF-alpha on the endothelium of murine aorta. *American journal of physiology Heart and*  
73 *circulatory physiology*.299(4):H1160-7.
- 74 48. Zimmerman MA, Reznikov LL, Raeburn CD, and Selzman CH. Interleukin-10 attenuates the response to  
75 vascular injury. *The Journal of surgical research*. 2004;121(2):206-13.
- 76 49. Han X, Kitamoto S, Wang H, and Boisvert WA. Interleukin-10 overexpression in macrophages suppresses  
77 atherosclerosis in hyperlipidemic mice. *FASEB J*.24(8):2869-80.
- 78 50. Isoda K, and Ohsuzu F. The effect of interleukin-1 receptor antagonist on arteries and cholesterol  
79 metabolism. *J Atheroscler Thromb*. 2006;13(1):21-30.

- 30 51. Khan F, Ray S, Craigie AM, Kennedy G, Hill A, Barton KL, et al. Lowering of oxidative stress improves  
31 endothelial function in healthy subjects with habitually low intake of fruit and vegetables: a randomized  
32 controlled trial of antioxidant- and polyphenol-rich blackcurrant juice. *Free Radic Biol Med.* 2014;72:232-7.
- 33 52. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the  
34 ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report  
35 of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol.* 2002;39(2):257-65.
- 36 53. George J, Hussain M, Vadiveloo T, Ireland S, Hopkinson P, Struthers AD, et al. Cardiovascular Effects of  
37 Switching From Tobacco Cigarettes to Electronic Cigarettes. *Journal of the American College of Cardiology.*  
38 2019;74(25):3112-20.
- 39 54. Padilla J, Johnson BD, Newcomer SC, Wilhite DP, Mickleborough TD, Fly AD, et al. Normalization of flow-  
40 mediated dilation to shear stress area under the curve eliminates the impact of variable hyperemic stimulus.  
41 *Cardiovascular Ultrasound.* 2008;6(1):44.
- 42 55. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, and Arthur JS. MSK1 and MSK2 are required for  
43 the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. *Mol Cell Biol.*  
44 2002;22(8):2871-81.
- 45 56. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88  
46 gene results in loss of IL-1- and IL-18-mediated function. *Immunity.* 1998;9(1):143-50.
- 47  
48



39 **Table 1:** STEMI patient and healthy volunteer characteristics

	<b>Healthy volunteers (N=28)</b>	<b>STEMI (N=35)</b>	<b>p value</b>
<b>Demographics</b>			
Age (Years)	60.0 (SD 10.5)	59.4 (SD 10.4)	>0.050 <sup>a</sup>
Gender (% Male)	60.7	91.4	<0.010 <sup>b</sup>
BMI (kg/m <sup>2</sup> )	24.3 (SD 3.2)	28.1 (SD 5.5)	<0.010 <sup>a</sup>
Systolic Blood Pressure (mmHg)	127.2 (SD 14.8)	117.0 (SD 14.8)	<0.010 <sup>a</sup>
Diastolic Blood Pressure (mmHg)	77.0 (SD 8.9)	70.9 (SD 9.7)	<0.050 <sup>a</sup>
Recruitment Delay (hours post PCI)	-	57.0 (SD 26.1)	-
<b>Past Medical History (%)</b>			
Diabetes Mellitus	-	16.7	-
Hypertension	-	37.5	-
Hypercholesterolemia	-	41.2	-
Angina/Myocardial Infarction	-	26.1	-
Stroke	-	-	-
<b>Smoking History (%)</b>			
Non-Smoker	78.6	17.4	<0.001 <sup>b</sup>
Current	7.1	34.8	<0.010 <sup>b</sup>

Ex-Smoker	14.3	47.8	<0.010 <sup>b</sup>
<b>Diagnosis STEMI (%)</b>			
Anterior STEMI	-	25.7	-
Posterior STEMI	-	2.9	-
Inferior STEMI	-	42.9	-
Anteroposterior STEMI	-	2.9	-
Anterolateral STEMI	-	2.9	-
Infer posterior STEMI	-	8.6	-
Inferolateral STEMI	-	2.9	-
Posterior Inferolateral STEMI	-	5.7	-
Unclassified STEMI	-	5.7	-
<b>Echocardiography (%)</b>			
LV Systolic Dysfunction	-	70.6	-
Mild	-	54.2	-
Moderate	-	47.1	-
Severe	-	4.2	-
<b>Medications (%)</b>			
Aspirin	-	97.1	-
Ticagrelor/Clopidogrel	-	97.1	-

Statins	-	97.1	-
ACEi/ARBs	-	82.4	-
Beta Blockers	-	88.2	-
Anticoagulants	-	14.7	-
Calcium Channel Blockers	-	11.8	-
Diuretics	-	23.5	-

# Graphical Abstract

medRxiv preprint doi: <https://doi.org/10.1101/2020.12.03.20243105>; this version posted December 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Figure 1




Figure 2




Figure 3





Figure 4



medRxiv preprint doi: <https://doi.org/10.1101/2020.12.03.20243105>; this version posted December 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 5






Figure 6


**A**




**F**




**B**




**G**




**C**



**D**



**E**




medRxiv preprint doi: <https://doi.org/10.1101/2020.12.03.20243105>; this version posted December 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary Data 1


Anisomycin (10 µg / mL) 1 hour

PD-184352 (10uM)	-	-	-	-	+	+	-	-	+	+	-	-	-	-
VX-745 (1uM)	-	-	-	-	-	-	+	+	+	+	-	-	-	-
SB-747581A (10uM)	-	-	-	-	-	-	-	-	-	-	+	+	-	-
PF3644022 (10uM)	-	-	-	-	-	-	-	-	-	-	-	-	+	+

medRxiv preprint doi: <https://doi.org/10.1101/2020.12.03.20243105>; this version posted December 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




# Supplementary Data 2



# Supplementary Data 3

**A**



**B**

